5 Science Park
395 Winchester Ave
80 articles with Arvinas Inc.
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience
NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup, M.D., has joined its board of directors. Dr. Smaldone Alsup, who is currently the Chief Scientific Officer and Chief Medical Officer for NDA Group, brings experience leading commercially successful product approvals and global regulatory strategies that have advanced programs th
Arvinas, Inc. announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00 per share, before underwriting discounts and commissions.
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock.
Presented initial data from the company’s ongoing Phase 1 clinical trials of ARV-110 and ARV-471.
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers
Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit
Arvinas Inc.,, a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit.
Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, announced the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer.
Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.
4/5/2019Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC ARV-110 at ASCO 2018 Genitourinary Cancers Symposium
The studies show that degradation of the androgen receptor with ARV-110 leads to inhibition of AR target gene expression and the proliferation of prostate cancer cell lines.
Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
ARV-378 is an orally bioavailable small molecule PROTAC designed to target and induce the degradation of the estrogen receptor protein, which plays a prominent role in the development of ER positive breast cancer.
Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium
Arvinas today announced the presentation of new preclinical data for its novel oral estrogen receptor alpha PROTAC program during a poster session at the 2017 SABCS.